Yumiko Aoyama

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

Taroh Satoh, Isamu Okamoto, Masaki Miyazaki et al. · Clinical Cancer Research · 2009 · 175 citations

Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma

Yumiko Aoyama, Atsunori Kaibara, Akitsugu Takada et al. · Investigational New Drugs · 2012 · 21 citations · Full text

Therapeutic Drug Monitoring, Oncology, Pharmacokinetic Modeling +15

Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non‐Hodgkin lymphoma

Yumiko Aoyama, Masataka Katashima, Taiji Sawamoto · Biopharmaceutics & Drug Disposition · 2012 · 13 citations

Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment

Yumiko Aoyama, Tetsuya Nishimura, Taiji Sawamoto et al. · Cancer Chemotherapy and Pharmacology · 2012 · 13 citations · Full text

Medical Writing Competency Model — Section 2: Knowledge, Skills, Abilities, and Behaviors

David B. Clemow, Bertil K.J. Wagner, Christopher Marshallsay et al. · Therapeutic Innovation & Regulatory Science · 2017 · 11 citations · Full text

Nursing, Writing Instruction, Creative Writing +9